Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Almonds are a rich matrix of different nutrients with demonstrated benefits on immune system. This proposal examines the effect of regular consumption of almonds on innate and adaptive immune system in healthy individuals with overweight regularly consuming a Western-style diet and unhealthy snacks.
In the last months, with the whole world grappling with COVID-19 and because like in many other diseases, the host immune system determines the progress of COVID-19 and the severity, there is a frantic race for finding treatment strategies based on current knowledge until effective vaccine is developed. Therefore, the modulation of inflammatory response and cytokine production using immunonutrition makes more sense than ever.
The almond is a tree nut, rich in fiber, vitamin E, biotin, minerals such as magnesium and phytonutrients, specifically flavonoids, plant sterols, phenolic acids and could have a potential beneficial role in immune system. However, beyond its beneficial role and down-lowering specific circulating cytokines in low-grade chronic inflammatory diseases, the role of almond on both innate and adaptive immune system has not been explored.
The investigators hypothesize that regular consumption of almonds will contribute to strengthening the immune system through the modulation of specific circulating miRNAs.
The primary objective is to evaluate the effect of almond consumption on the maturation of innate lymphoid cells (ILCs).
Secondarily, the insvestigators aims to:
Examine the effect of regular consumption of almonds in the context of a Western-style diet on: a) innate immune system through the analysis of other blood cell populations including monocytes and lymphocyte's subsets (T-cells, B-cells). b) adaptive immune system assessed by: b.1) circulating inflammatory markers and b.2) ex-vivo ability for peripheral blood mononuclear cell (PBMC) to produce cytokines.
c) circulating miRNAs, focusing in immune-related miRNAs.
To investigate whether changes in miRNAs mediate the effect of almonds on ILCs activity and the other innate and adaptive immune system indicators analysed.
The expected results would enhance understanding of the role of almonds in immune function, to establish the basis of new research for the promotion of the health benefits of nuts in immune-related diseases and facilitate the use of personalized nutrition to improve human health.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Almond intervention | Experimental | Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds |
|
| Control | Active Comparator | Participants will be provided with isocaloric snacks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Almond intervention | Behavioral | Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in innate myeloid and lymphoid cells | CD45+, CD103+, CD56+, CD14+,CD16+, CD8+, CD19+, CD4+, CD3+, CD36+, CD44+, ROR γ t, NKp46+, FoxP3+ will be assessed by means of flow cytometry in cryopreserved cells. | These outcomes will be assessed at baseline and at 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in lymphocyte subsets | Lymphocyte subsets will be measured using Ficoll-Paque (GE Healthcare) density gradient centrifugation and flow cytometry. Results will be expressed in 10 (9)/L cells | These outcomes will be assessed at baseline and at 8 weeks |
| Changes in immune cells activity assessed by citokyne production |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in circulating miRNAs | 20 circulating miRNA will be measured using TaqMan MicroRNA Assays. Results will be expressed as relative increase or decrease | These outcomes will be assessed at baseline and at 8 weeks |
| Changes in gut microbiota composition |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Monica Bullo, Prof | Pere Virgili | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| IISPV | Reus | Tarragona | 43201 | Spain |
Data sharing will be upon request directly to the PI
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Control | Behavioral | Participants will be provided with isocaloric snacks |
|
Innate lymphoid and myeloid cells activity will be assessed in cryopreserved PBMCs. Inflammation mediators ( such as hs-CRP, IL1, IL2, IL4, IL-6, IL-7, IL-10, TNFα, IFN-γ, TGF-β, TLR4, NOD1) will be assessed with chemical assays (ELISA). Results will be expressed as mass/volume |
| These outcomes will be assessed at baseline and at 8 weeks |
| Changes in immune cells activity assessed by adaptor molecules | A study of the molecular signaling using Western blot qauntification of adaptor molecules that play a pivotal role in immune cell activation through Toll-like receptors and therefore are good markers for specific immune cells activities | These outcomes will be assessed at baseline and at 8 weeks |
| Changes in inflammatory markers and related molecules in plasma/serum | Several citokynes related immune cells (i.e TNF, IL6, IL1) and other circulating inflmmatory markers (i.e. CRP, amiloid) will be measured by ELISA related methods. Results will be expressed in mass/volume | These outcomes will be assessed at baseline and at 8 weeks |
16S RNA will be sequenced and functional in silico analyses using existing datasets will be conducted. Data will be expressed in relative abundace (OTUS/ASV) at genus, family and/or specie level
| These outcomes will be assessed at baseline and at 8 weeks |
| Changes in gut microbiota function | Fecal targeted quantitative metabolomic multi-platform analyses will be conducted to identify changes in fecal metabolites related to the intervention (different metabolites including lipid species, aminoacids, bile acids, short-chain fatty acids...will be included) | These outcomes will be assessed at baseline and at 8 weeks |
| Changes in circulating metabolites concentrations | We will use a multi-platform targeted/untargeted approach to identify/quantify metabolites related to the intervention and outcomes. (different metabolites including lipid species, aminoacids, bile acids, short-chain fatty acids...will be included) | These outcomes will be assessed at baseline and at 8 weeks |